Alex Leech, Alchemab CEO (SV Health Investors)

Alchemab bags fresh round of in­vestors for tar­get-ag­nos­tic an­ti­body de­vel­op­ment for Hunt­ing­ton's, Covid-19

With a “tar­get-ag­nos­tic” ap­proach to an­ti­body de­vel­op­ment, the UK’s Alchemab has used lessons learned from pa­tients with re­sis­tance to cer­tain dis­eases to chase af­ter con­di­tions as far apart as Hunt­ing­ton’s and Covid-19. Now, in­vestors are jump­ing on board the con­cept with an $86 mil­lion Se­ries A.

The pro­ceeds will go to­ward ad­vanc­ing the com­pa­ny’s tar­get-ag­nos­tic drug dis­cov­ery pro­gram, a re­lease said. That ap­proach looks at the an­ti­body reper­toires of pa­tients who show re­sis­tance to typ­i­cal­ly de­struc­tive dis­eases re­gard­less of ge­net­ic dis­po­si­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.